What is it? Why is it important?

Corrective and Preventive Actions (CAPA) are adaptations and improvements taken to eliminate causes of non-compliance.

 

CAPAs include a set of actions that require:

  • A root-cause analysis of the situation or event, in order to explain why non-compliance did occur
  • The implementation of corrective actions that allows for a non-compliant activity to return to compliance
  • The implementation of preventive actions with the aim to avoid the reoccurrence of the non-compliant event

 

When handling CAPAs a risk-based approach should be used. A risk-based approach assesses the potential impact of non-compliances, and helps to define the scope and required resources needed for CAPA implementation.

 

After an audit or inspection, the SP-INV writes a CAPA plan that lists a response on how to handle non-compliance (findings) noted during an audit or inspection.

What do I need to do?

As a SP-INV, ensure to establishing a risk-based Quality Management System during study planning and development, this allows:

 

CAPA management after an audit or inspection (e.g. Swissmedic)

  • Perform a root-cause analysis of non-compliances/findings from the audit/inspection report
  • Assess the implementation of corrective actions, and whether they can be implemented. Implement, without delay, corrective actions regarding high-risk non-compliances (e.g. participant safety, data quality)
  • Assess the implementation of preventive actions, and decide on required quality processes and /or risk control-measures
  • Document corrective and preventive actions in a CAPA plan, include timelines until CAPA resolution
  • Submit the CAPA plan for approval to the audit/inspection responsible entities
  • Once approved, implement the CAPA plan within defined timelines
  • In the event of a re-audit/re-inspection, the implementation of the previously approved CAPA plan is re-evaluated

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guidelines

  • Glossary: Inspection, Audit
  • 3.10 Quality management
  • 3.10.1 Risk Management
  • 3.11.2 Audit

ICH E8(R1) – see in particular

  • 3.2 Critical to Quality Factors

ISO 9001 (access liable to costs) – see in particular section 

  • QMS Requirements

ISO 19011 (access liable to costs) – see in particular section

  • Guidelines for auditing management systems

EMA – see in particular

  • Guidance for the preparation of good clinical practice inspection reports and communication of inspection findings

 

Documents

Abbreviations
  • CAPA – Corrective and Preventive Actions
  • CtoQ – Critical to Quality
  • CTU – Clinical Trials Unit
  • EMA – European Medicines Agency
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ISO – International Organization for Standardization
  • SP-INV – Sponsor-Investigator
Conduct ↦ Quality and Risk ↦ Regulatory Inspections ↦ Corrective and Preventive Actions
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Quality and Risk ↦ Regulatory Inspections ↦ Corrective and Preventive Actions